DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR IXABEPILONE
➤ Get the DrugPatentWatch Daily Briefing
« Back to Dashboard
All Clinical Trials for Ixabepilone
| Trial ID |
Title |
Status |
Sponsor |
Phase |
Start Date |
Summary |
| NCT00004927 ↗ |
BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy |
Completed |
Memorial Sloan Kettering Cancer Center |
Phase 1 |
1999-07-01 |
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die.
PURPOSE: Phase I trial to study the effectiveness of BMS-247550 in treating patients who
have advanced solid tumors that have not responded to previous therapy.
|
| NCT00004927 ↗ |
BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy |
Completed |
National Cancer Institute (NCI) |
Phase 1 |
1999-07-01 |
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die.
PURPOSE: Phase I trial to study the effectiveness of BMS-247550 in treating patients who
have advanced solid tumors that have not responded to previous therapy.
|
| NCT00004927 ↗ |
BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy |
Completed |
Bristol-Myers Squibb |
Phase 1 |
1999-07-01 |
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die.
PURPOSE: Phase I trial to study the effectiveness of BMS-247550 in treating patients who
have advanced solid tumors that have not responded to previous therapy.
|
| NCT00005807 ↗ |
BMS-247550 in Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer |
Completed |
National Cancer Institute (NCI) |
Phase 1 |
2000-07-01 |
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die.
PURPOSE: Phase I trial to study the effectiveness of BMS-247550 in treating patients who
have metastatic, recurrent, or locally advanced, ovarian cancer, breast cancer, or
metastatic or unresectable solid tumors.
|
| >Trial ID |
>Title |
>Status |
>Phase |
>Start Date |
>Summary |
Clinical Trial Conditions for Ixabepilone
Condition Name
| Condition Name for Ixabepilone |
| Intervention |
Trials |
| Breast Cancer |
23 |
| Metastatic Breast Cancer |
18 |
| Unspecified Adult Solid Tumor, Protocol Specific |
9 |
| Stage IV Breast Cancer |
7 |
| [disabled in preview] |
0 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Condition MeSH
| Condition MeSH for Ixabepilone |
| Intervention |
Trials |
| Breast Neoplasms |
47 |
| Carcinoma |
11 |
| Adenocarcinoma |
9 |
| Prostatic Neoplasms |
8 |
| [disabled in preview] |
0 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Clinical Trial Locations for Ixabepilone
Trials by Country
| Trials by Country for Ixabepilone |
| Location |
Trials |
| United States |
599 |
| Italy |
24 |
| Japan |
18 |
| United Kingdom |
15 |
| Argentina |
12 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Trials by US State
| Trials by US State for Ixabepilone |
| Location |
Trials |
| California |
30 |
| New York |
30 |
| Maryland |
29 |
| Florida |
28 |
| Texas |
26 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Clinical Trial Progress for Ixabepilone
Clinical Trial Phase
| Clinical Trial Phase for Ixabepilone |
| Clinical Trial Phase |
Trials |
| Phase 3 |
7 |
| Phase 2 |
65 |
| Phase 1/Phase 2 |
12 |
| [disabled in preview] |
30 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Clinical Trial Status
| Clinical Trial Status for Ixabepilone |
| Clinical Trial Phase |
Trials |
| Completed |
69 |
| Terminated |
19 |
| Active, not recruiting |
12 |
| [disabled in preview] |
6 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Clinical Trial Sponsors for Ixabepilone
Sponsor Name
| Sponsor Name for Ixabepilone |
| Sponsor |
Trials |
| National Cancer Institute (NCI) |
52 |
| Bristol-Myers Squibb |
28 |
| R-Pharm |
18 |
| [disabled in preview] |
7 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Sponsor Type
| Sponsor Type for Ixabepilone |
| Sponsor |
Trials |
| Industry |
68 |
| Other |
55 |
| NIH |
53 |
| [disabled in preview] |
0 |
This preview shows a limited data set
Subscribe for full access, or try a Trial |
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
